Akari Therapeutics (AKTX) Upgraded at ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Akari Therapeutics (NASDAQ:AKTX) from a hold rating to a buy rating in a research report sent to investors on Thursday.

NASDAQ AKTX opened at $1.90 on Thursday. Akari Therapeutics has a 52-week low of $1.62 and a 52-week high of $5.49. The company has a market cap of $22.38 million, a P/E ratio of -6.79 and a beta of -5.95.

Akari Therapeutics (NASDAQ:AKTX) last posted its earnings results on Friday, August 17th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. On average, analysts anticipate that Akari Therapeutics will post -1.27 earnings per share for the current year.

A hedge fund recently raised its stake in Akari Therapeutics stock. Hikari Power Ltd grew its position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 32.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 843,849 shares of the biopharmaceutical company’s stock after acquiring an additional 207,506 shares during the quarter. Hikari Power Ltd owned 7.16% of Akari Therapeutics worth $1,646,000 at the end of the most recent reporting period. 16.79% of the stock is owned by institutional investors.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.

Recommended Story: What are the most popular ETFs

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply